Bimatoprost 0.3% | Finasteride 0.1% | GHK-Cu 0.5% | Minoxidil 20% | Tretinoin 0.05%

Route: Topical application to the affected scalp area.

• Apply the prescribed quantity to dry scalp using the provided dropper or applicator; part the hair to ensure scalp contact.
• Gently massage into the scalp; do not rinse immediately—allow at least 4 hours before washing hair.
• Apply at the same time each day (evening application preferred, particularly for tretinoin, which increases photosensitivity).
• Wash hands thoroughly after application to prevent inadvertent facial or mucosal contact.
• Allow scalp to dry before applying other topical scalp products.

The prescriber determines the volume, frequency, and duration of application. General clinical framework:

• Typically 1 mL applied to the affected scalp area once daily.
• Clinical response may take 3–6 months; prescriber should evaluate response at 6 and 12 months.
• Continued use is generally required to maintain benefit; hair loss may resume upon discontinuation.
• Final dosing instructions are established by the prescribing clinician based on the patient's alopecia pattern, degree, and response.

• Minoxidil: Converted to minoxidil sulfate by follicular sulfotransferase; opens ATP-sensitive K⁺ channels in vascular smooth muscle and dermal papilla cells, promoting microvascular blood flow, prolonging anagen phase, and increasing follicular size.
• Finasteride (topical 0.1%): Competitively inhibits type II and III 5-alpha-reductase in scalp tissue, reducing local conversion of testosterone to DHT, thereby mitigating androgen-mediated follicular miniaturization with substantially reduced systemic DHT effects compared to oral dosing.
• Bimatoprost: Synthetic prostamide and prostaglandin FP receptor agonist; stimulates prostanoid receptors expressed in dermal papilla and outer root sheath of hair follicles, inducing telogen-to-anagen transition and prolonging the anagen phase.
• GHK-Cu: Copper tripeptide-1 chelates copper ions; modulates expression of over 4,000 genes, stimulates VEGF (increasing follicular microcirculation), promotes dermal papilla fibroblast-like cell growth, and upregulates Wnt/β-catenin signaling linked to anagen induction.
• Tretinoin: RAR agonist that increases skin permeability and minoxidil absorption through the stratum corneum; additionally promotes follicular cell turnover and may have mild anti-inflammatory effects in the perifollicular dermis.

This multi-target topical formulation is prescribed for patients with androgenetic alopecia or other alopecias where single-agent therapy has been insufficient. The combination addresses androgen-mediated follicular miniaturization (finasteride), follicular cycle dysregulation (bimatoprost, minoxidil), follicular microenvironment support (GHK-Cu), and drug delivery optimization (tretinoin).

Prescriber monitoring:

• Assess scalp for irritation, erythema, or contact dermatitis from tretinoin or high-concentration minoxidil.
• For reproductive-age women and women of childbearing potential: finasteride is teratogenic (Category X); confirm pregnancy status and effective contraception before prescribing.
• An initial shedding phase (telogen effluvium) may occur in the first 4–8 weeks; counsel patients to continue therapy.
• Monitor blood pressure in patients using high-concentration minoxidil (20%) if systemic absorption is of concern.
• Bimatoprost may cause periocular hyperpigmentation or eyelash changes if product contacts the periorbital area; counsel patients to wash hands thoroughly.

Contraindications:

• Pregnancy or women who may become pregnant (finasteride, tretinoin—both teratogenic)
• Known hypersensitivity to any ingredient
• Scalp infection, inflammation, or open wounds at the application site

Warnings & Precautions:

• Finasteride teratogenicity: May cause abnormalities of external genitalia of a male fetus; women of childbearing potential must not use this product.
• Photosensitivity: Tretinoin increases UV sensitivity; advise scalp sun protection.
• Systemic minoxidil absorption: At 20% concentration, systemic cardiovascular effects (tachycardia, fluid retention, hypotension) are theoretically possible, especially with damaged scalp or large application areas.
• Bimatoprost periocular effects: Increased iris pigmentation and eyelash changes have been reported with prostaglandin analogs; avoid periorbital contact.

Drug Interactions:

• Concurrent systemic minoxidil or antihypertensives: additive hypotensive effect possible.
• Systemic cyclosporine may exacerbate hypertrichosis with topical minoxidil.
• Finasteride: no significant CYP drug interactions documented for topical low-dose use.

Common Side Effects: Scalp erythema, dryness, pruritus, and scaling (tretinoin, high-concentration minoxidil); initial telogen effluvium (minoxidil); periocular hyperpigmentation risk if bimatoprost contacts periorbital skin; sexual dysfunction is rare with topical low-dose finasteride but has been reported.

Store in a cool, dark location (15–25°C / 59–77°F); refrigeration (2–8°C) may be recommended—confirm with Genesis Compounding labeling. Protect from light; brown or amber bottles reduce photodegradation of bimatoprost and tretinoin. Do not freeze. Keep tightly capped. Use before the beyond-use date. Keep out of reach of children.

Why are five ingredients combined in one solution?

Androgenetic alopecia is a multifactorial condition. This formulation simultaneously targets androgen-mediated follicular miniaturization (finasteride), follicular blood flow and anagen prolongation (minoxidil, bimatoprost), follicular microenvironment support (GHK-Cu), and penetration enhancement (tretinoin). Each ingredient addresses a different pathophysiologic axis for potentially additive benefit.

How long before I see results?

Hair growth is a slow process. Improvement in hair density or shedding may first be observed at 3–6 months, with more significant results at 9–12 months. An initial shedding phase in the first 4–8 weeks is expected and does not indicate treatment failure.

Is the topical finasteride safe for women?

Women who are pregnant or may become pregnant must not use this product due to the risk of fetal harm from finasteride. Women of childbearing potential should discuss effective contraception with their prescriber before using this formulation.

Is this product FDA-approved?

This is a 503A compounded preparation from Genesis Compounding, prepared for a specific patient per a prescriber's order. None of the five-ingredient combination is FDA-approved as a finished product, though each individual ingredient has established clinical pharmacology in hair loss management.

Should I apply this in the morning or evening?

Evening application is generally preferred because tretinoin increases photosensitivity and is degraded by UV light. Applying at night avoids sun exposure on the scalp. Follow your prescriber's specific instructions.